FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 2

ATTORNEY DOCKET NO. APPLICATION NO.		
6102-000069/US	10/623,864	
APPLICANT		
Schacht, D.W., et al		
FILING DATE	GROUP	
July 22, 2003	1617	

U.S. F	U.S. PATENT DOCUMENTS					
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
		2004/0013620	Jan 22, 2004	Klose et al.	424/59	May 2, 2003
		2010/0311806	Dec 9, 2010	Wolff, et al.	514/438	Aug 27, 2010
		3,797,494	Mar 19, 1974	Zaffaroni,	424/434	Aug 9, 1971
		4,588,580	May 13, 1986	Gale et al.	424/449	Jul 23, 1984
		5,217,718	June 8, 1993	Colley et al.	424/449	Sep 17, 1991
		5,500,222	Mar 19, 1996	Lee et al.	424/448	Feb 15, 1995
		5,676,968	Oct 14, 1997	Lipp et al.	424/448	May 3, 1995
		5,932,240	Aug 3, 1999	D'Angelo et al.	424/449	Dec 8, 1997
		7,279,178	Oct 9, 2007	Berthold	424/443	Jul 5, 2001

FORE	FOREIGN PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
		DE 10060550	Apr 18, 2002	DE	A61K31/216	X (Abstract only)	
		FR 2792529	Oct 27, 2000	FR	A61K31/42	X (Abstract only)	
		WO 98/00126	Jan 8 1998	PCT	A61K 31/215		
		WO 99/01795	Jan 14 1999	PCT	B41C1/10		
		WO 02/26217	Apr 4 2002	PCT	A61K 9/70		
		WO 2002/045699	Jun 13 2002	PCT	A61K 31/216	X (Abstract only)	
		WO 02/074286	Sep 26 2002	PCT	A61K 9/70		
		WO 02/089777	Nov 14 2002	PCT	A61K 9/70		
		WO 2004/012719	Feb 12 2004	PCT	A61K 9/70		
		WO 2004/012730	Feb 12 2004	PCT	A61K 31/38		
		WO 2004/058247	Jun 15 2004	PCT	A61K 31/381	X (Abstract only)	

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 2 of 2

ATTORNEY DOCKET NO.	EY DOCKET NO. APPLICATION NO.		
6102-000069/US	10/623,864		
APPLICANT			
Schacht, D.W. et al			
FILING DATE	GROUP		
July 22, 2003	1617		

Ref. Desig.	Examiner's Initials	
		Goodman and Gilman's, (1990) The Pharmacological Basis of Therapeutics, Pergamon Press, 8 th ed, page 160
		The Merck Index, Thirteenth Edition (2001) "7024. Oxybutynin" Whitehouse Station, NJ: Merck & Co., Inc., pg. 1245
		Miyamoto <i>et al.</i> (1994) Analyst_119, 1489-1492
		Nugroho et al. (2004) Pharmaceutical Research, 844-850
		Roy (1990) "Transdermal delivery of narcotic analgesics: PH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanil." Pharmaceutical Research, New York, NY, US, vol. 7, no. 8, pp 842-847, XP002923066
		Stryer, (1996) Biochemestry, W.H. Freeman and Company, New York, pages 20-22 and 25
		http://www.accessdata.fda.gov (USFDA label for NEUPRO (2007) retrievied by CA examiner from Drugs@FDA database)
		http://www.neupro.com (Neupro recall letter to physicians (2008), retrieved from CA examiner from US NEUPRO homepage, attached)
		Office Action, dated October 8, 2010 issued in U.S. Application No. 10/936,620
		Office Action, dated January 04, 2011 issued in U.S. Application No.10/627,990
		Office Action, dated August 3, 2010 issued in U.S. Application No.10/517,157
		Office Action, dated November 9, 2010 issued in U.S. Application No.12/114,348
		Office Action, dated October 1, 2010 issued in U.S. Application No.10/429,283